The European Patent Office EPO intends to approve Iconovo’s patent application for the inhaler platform ICOone® (Communication under Rule 71(3) EPC). The patent describes the single-dose inhaler ICOone, which is currently being used in three innovative collaborative projects for the administration of e.g., oxytocin and covid-19 vaccine. Iconovo already has a well-established patent portfolio for ICOone® in Sweden, Europe (EPO), the USA, China and India.
Iconovo’s innovative inhaler platform ICOone® enables the administration of vaccines and bioactive molecules in a simple and cost-effective way. Since the drug is dispensed as a dry powder in ICOone®, no expensive cold storage transportation is required. Furthermore, ICOone® enables easy and safe handling for both patients and healthcare professionals. Risks connected with the handling of disposable syringes and used needles are avoided since the pharmaceutical is inhaled.
“-This patent protects a unique property of ICOone that makes it very easy to manufacture, which contributes to a very low manufacturing cost. In the event of a pandemic, it is important to reach a large population worldwide in a cost-effective way. In many markets, the manufacturing cost is decisive for the choice of product”, says Dr Orest Lastow, Chief Technical Officer at Iconovo.
Read the pressrelease here